TABLE S1. Timing of Safety, Psychiatric, and Cognitive Assessments

	Screening Visit 1	Screening Visit 2	Day –1	Day 7	Day 14	Day 28	Day 42	Day 56	Day 84	Follow-Up (Day 98)
Adverse Event Monitoring		X	X	X	X	X	X	X	X	X
MCCB	X		X				X		X	
UPSA-2			X						X	
CANTAB	X	X				X		X		
PANSS	X	X	X			X	X		X	
NSA-16			X		X		X		X	
CGI-S			X		X		X		X	
CDSS	X									

MCCB = MATRICS Consensus Cognitive Battery, UPSA-2 = University of California Performance-Based Skills Assessment-2, CANTAB = Cambridge Neuropsychological Test Automated Battery (CANTAB), PANSS = Positive and Negative Syndrome Scale, NSA-16 = 16-item Negative Symptom Assessment, CGI-S = Clinical Global Impression-Severity, CDSS = Calgary Depression Scale for Schizophrenia.

TABLE S2. Summary of Adverse Events

	Placebo N=67		**ABT-126** **10 mg** N=69		**25 mg** N=67		**Any dose** N=136	
	N	%	N	%	N	%	N	%
Summary								
Any adverse event	38	57	35	51	39	58	74	54
Severe adverse event	4	6	3	4	4	6	7	5
Serious adverse event	3	5	1	1	5	8	6	4
Deaths	0	0	0	0	0	0	0	0
Discontinued due to adverse event	5	8	4	6	8	6	13	6
Any adverse events reported by ≥3% of subjects treated with ABT-126								
Diarrhea	2	3	5	7	5	8	10	7
Dizziness	1	2	7[a]	10[a]	3	5	10	7
Headache	6	9	3	4	7	10	10	7
Nausea	5	8	5	7	3	5	8	6
Fatigue	1	2	4	6	3	5	7	5
Nasopharyngitis	2	3	3	4	4	6	7	5
Insomnia	3	5	0	0	5	8	5	4
Blood creatine phosphokinase increased	0	0	2	3	3	5	5	4
Upper respiratory tract infection	3	5	3	4	2	3	5	4

[a] Two-sided p value compared to placebo, 0.063.